Skip to main content

Table 3 Inhibitory effect of VX-745 on hyperalgesia in the Hargraeves model

From: P38 MAP kinase inhibitors as potential therapeutics for the treatment of joint degeneration and pain associated with osteoarthritis

COMPOUND PAW WITHDRAWAL TIME PRE-DRUG TREATMENT (Seconds) PAW WITHDRAWAL TIME POST-DRUG TREATMENT (Seconds)
Vehicle 11.5 ± 0.8 7.4 ± 0.5
Indomethacin (10 mg/kg) 12.3 ± 0.9 16.3 ± 1.2*
VX-745 (30 mg/kg) 10.6 ± 0.4 14.9 ± 0.6*
VX-745 (10 mg/kg) 11.7 ± 0.8 12.1 ± 0.7*
VX-745 (3 mg/kg) 12.0 ± 0.7 9.4 ± 1.0*
  1. The data are presented as the time for paw withdrawal from the heat source in seconds and are the mean ± S.E.M. from 10 rats per treatment group. The asterisk denotes a statistically significant difference (p < 0.05) between the vehicle and drug treatment groups.